DDInter1073 DDInter1676
Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the initiation of bacterial protein synthesis - more specifically, it binds to the 23S ribosomal RNA of the 50S subunit[A11227,A199050] and, in doing so, prevents the formation of the 70S initiation complex which is essential for bacterial reproduction. Linezolid was initially approved in 2000 and was the first member of the oxazolidinone antibiotic class. A second member of this class, [tedizolid], was approved by the FDA in 2014 and is considered generally more effective and tolerable than its predecessor.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Linezolid {u} (Compound) resembles {v} (Compound) Rivaroxaban
Linezolid {u} (Compound) binds {v} (Gene) MAOB
Linezolid {u} (Compound) upregulates {v} (Gene) ZFP36
Linezolid {u} (Compound) is included by {v} (Pharmacologic Class) Oxazolidinones
Linezolid {u} (Compound) downregulates {v} (Gene) IER3
Linezolid {u} (Compound) causes {v} (Side Effect) Thrombophlebitis
Linezolid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chlorpheniramine
Linezolid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dapsone
Linezolid {u} may lead to a major life threatening interaction when taken with {v} Epinephrine
Linezolid {u} may lead to a major life threatening interaction when taken with {v} Cladribine
Linezolid (Compound) resembles Rivaroxaban (Compound)
Linezolid (Compound) binds MAOB (Gene)
Linezolid (Compound) upregulates ZFP36 (Gene)
Linezolid (Compound) is included by Oxazolidinones (Pharmacologic Class)
Linezolid (Compound) downregulates IER3 (Gene)
Linezolid (Compound) causes Thrombophlebitis (Side Effect)
Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Dapsone
Linezolid may lead to a major life threatening interaction when taken with Epinephrine
Linezolid may lead to a major life threatening interaction when taken with Cladribine